ASSUREDAI Trademark Application - Mobile Health Software

USPTO published Intent-to-Use trademark application TM99736906 for ASSUREDAI filed March 31, 2026. The application covers downloadable mobile application software for health monitoring under Nice Class 009 (Computing & Electronics). This publication initiates the examination process but the mark is not yet registered.

ZUNSCREEN Intent to Use Trademark Application

USPTO received an Intent to Use trademark application for ZUNSCREEN (Serial No. TM99736892) filed March 31, 2026, covering online retail store services and eyeglass/optical products including prescription ophthalmic eyeglasses, sunglasses, frames, lenses, cases, and magnets in International Class 009. The application establishes a priority filing date but does not create immediate compliance obligations for third parties.

MAILE AI Trademark Application for Construction Document Analysis

The USPTO received a trademark application (TM99737303) for MAILE AI, covering AI-powered software for analyzing construction documents, providing plan review assistance, identifying code compliance issues, and supporting building permitting workflows. The application, filed March 31, 2026, is currently in Intent to Use status.

Veeva Systems - Delisting Determination Notice

SEC Form 8-K filed by Veeva Systems Inc. (CIK 0001840317) disclosing receipt of a delisting determination from the NYSE under Item 3.01 of Form 8-K. The company has been notified that it fails to satisfy continued listing standards, triggering potential removal from the exchange and transfer of trading to over-the-counter markets.

Chimeric Antigen Receptors Binding Nectin-4 for Cancer Treatment

The USPTO published patent application US20260091114A1 by Fred Hutchinson Cancer Center disclosing Chimeric Antigen Receptors (CARs) with binding domains that target Nectin-4, derived from murine antibody M22-321b41.1. The CARs are designed for expression in immune cells to treat Nectin-4-expressing cancers including bladder, breast, ovarian, esophageal, lung, colorectal, and pancreatic cancers. Application No. 19112145 was filed September 14, 2023.

PSMA-STEAP1 Dual Variable Domain Immunoglobulin DVD-Ig Molecules and Drug Conjugates

AbbVie Inc. filed US Patent Application US20260091121A2 for dual variable domain immunoglobulin (DVD-Ig) molecules binding human PSMA and STEAP1 antigens and their drug conjugates. The application (No. 18958236) was published on April 2, 2026 following filing on November 25, 2024. Competitors should monitor this IP position as it may cover cancer therapeutic constructs targeting these prostate cancer-associated antigens.

Hybrid Antibody-Peptide Molecule for Autoimmune Dermatitis

Université Toulouse III – Paul Sabatier has published patent application US20260091122A1 for a hybrid molecule combining an antibody Fc fragment with a peptide targeting autoreactive lymphocytes involved in autoimmune dermatitis. The invention covers the covalent bonding of the Fc portion to the targeting peptide and its therapeutic applications for treating autoimmune skin conditions.

Click-to-Release Biotech Patent for Proteins and Peptides

The USPTO published patent application US20260091124A1 by inventor Michael Lukesch for a click-to-release technology involving modified peptides or proteins combined with bioorthogonally modified drugs. The application, filed September 20, 2023, and published April 2, 2026, covers bioorthogonal functional groups that enable targeted drug delivery systems for therapeutic applications.

Nanocomposite for Targeted Degradation of Pathogenic Proteins

USPTO published patent application US20260091129A1 by inventors Zhang et al. disclosing a nanocomposite system for targeted degradation of pathogenic proteins using a maleimide-PEG-PLA nanocarrier with cationic lipids and protein-targeting binding peptides. The invention enables degradation of protein aggregates through autophagy pathways, addressing limitations of PROTAC and LYTAC technologies, with applications in anti-tumor treatments and Huntington's disease.

AAV NDP Gene Therapy for NDP-Related Diseases Including Norrie Disease and Retinopathy

USPTO published patent application US20260091131A1 by University of Massachusetts inventors disclosing AAV constructs encoding wildtype or codon-optimized NDP gene sequences for treating Norrie disease, diabetic maculopathy, retinopathy, and other NDP-related retinal diseases. The application, filed October 10, 2023, covers methods of administration including intravitreal injection for retinal neovascularization and exudation conditions.